FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The strategic partnership for 6 gigawatts of GPU deployment challenges Nvidia's dominance and signals a new era in AI infrastructure.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
Taiwan Semiconductor hits a 52-week high while AMD and OpenAI announce a landmark chip deal, signaling sustained bullish momentum for chipmakers.
The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.